Harriet Teare


Having left HeLEX at the University of Oxford in 2020, Dr Harriet Teare is now Research Leader at RAND Europe, Cambridge.  

Dr Harriet Teare was a Researcher in Healthcare and Policy, contributing to a programme of work addressing Global Access to Medicines (in collaboration with members of the Structural Genomics Consortium, Oxford). She had previously provided research governance and ethical support to the DIRECT project – an IMI-JU funded collaboration exploring stratification in Type 2 diabetes, the Rudy Study – a research network for rare diseases of the blood, bone and joints, and led a work package focusing on consent in the Genetics Clinic of the Future – a Horizon 2020 project mapping the complex challenges that will need to be tackled to introduce genome sequencing more widely into the clinic. Harriet obtained a DPhil in Organic and Medicinal Chemistry from Merton College, Oxford, and previously worked as a Senior Policy Advisor at Cancer Research UK, focusing on policy issues relating to science and research, and public health.

Harriet remains an Academic Affiliate of HeLEX.


Research Interests

As a multidisciplinary researcher working at the interface between ethics, governance and biomedical research I am interested in the role and expectations of patients amidst changing technology, and how the future of healthcare delivery might influence access.

Current approaches to healthcare are failing as populations grow and delivery becomes more expensive. Improving mechanisms that allow patients throughout the world to access therapies and treatments to realise their best possible health is vital.

Digital technologies may offer part of the solution to address this challenge, provided that the tools implemented are genuinely useful to both users (patients) and healthcare professionals. These tools are being developed and implemented at all stages in the healthcare pathway, including in the early stages of drug development, through to the interaction of patients with the healthcare system. At this point in their development, it is important to consider how implementation might affect different individuals and groups accessing healthcare, understanding both the opportunities and challenges for access

Research projects & programmes

DIRECT Dynamic Consent